2-硝基-5-(对甲苯磺酰基)呋喃 | 343351-67-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-硝基-5-(对甲苯磺酰基)呋喃
• 中文别名: 2-[(4-甲基苯基)磺酰基]-5-硝基呋喃；2-（4-甲基苯基）磺酰基-5-硝基呋喃
• 英文名称: 2-[(4-Methylphenyl)sulfonyl]-5-nitrofuran
• 英文别名: 2-(4-methylphenyl)sulfonyl-5-nitrofuran
• CAS: 343351-67-7
• 化学式: C11H9NO5S
• 分子量: 267.26
• InChiKey: GAUHIPWCDXOLCZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  102
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• COMBINATION OF A UBIQUITIN-CONJUGATING ENZYME COMPLEX INHIBITOR AND ANTIHYPERTENSIVE AND / OR HYPOGLYCEMIC DRUGS IN DIABETIC KIDNEY DISEASE
  申请人：Universita di Bari

  公开号：EP3773545A1

  公开（公告）日：2021-02-17
• RATIONAL THERAPEUTIC TARGETING OF ONCOGENIC IMMUNE SIGNALING STATES IN MYELOID MALIGNANCIES VIA THE UBIQUITIN CONJUGATING ENZYME UBE2N
  申请人：Children's Hospital Medical Center

  公开号：EP3983533A1

  公开（公告）日：2022-04-20
• METHODS, PHARMACEUTICAL COMPOSITIONS, THERAPEUTIC SYSTEMS, AND COMPOUNDS FOR TREATING B CELL MALIGNANCIES
  申请人：UNIVERSITY OF ROCHESTER

  公开号：US20150010643A1

  公开（公告）日：2015-01-08

  This invention relates to a method of treating B cell malignancies, which involves administering to a subject a compound having a structure of formula (I) to cause cell death of a B cell malignancy, thereby treating the B cell malignancy in the subject. Also disclosed are a method of causing cell death of malignant B cells, pharmaceutical compositions and therapeutic systems comprising a compound having a structure of formula (I), and a compound having a structure of formula (I).
• COMBINATION OF A UBIQUITIN-CONJUGATING ENZYME COMPLEX INHIBITOR AND ANTIHYPERTENSIVE AND/OR HYPOGLYCEMIC DRUGS IN DIABETIC KIDNEY DISEASE
  申请人：UNIVERSITÀ DEGLI STUDI DI BARI ALDO MORO

  公开号：US20210015785A1

  公开（公告）日：2021-01-21

  The present invention relates to a composition comprising at least one inhibitor of the enzymatic complex conjugating ubiquitin Ubc13/Uev1a and at least one anti-hypertensive agent inhibiting the renin-angiotensin-aldosterone system and/or a hypoglycemic agent. Medical uses and pharmaceutical compositions comprising this composition also fall within the scope of the present invention. In particular, this composition can be used for the treatment or prevention of the renal fibrotic damage, in particular in patients suffering from diabetes.
• METHODS AND COMPOSITIONS FOR TREATMENT OF MYELODYSPLASTIC SYNDROMES AND/OR ACUTE MYELOID LEUKEMIAS
  申请人：Children's Hospital Medical Center

  公开号：US20210299102A1

  公开（公告）日：2021-09-30

  Disclosed are methods for treating a myelodyspastic syndrome (MDS) and/or an acute myeloid leukemia (AML) in an individual in need thereof. Further disclosed are compositions for use in the disclosed methods, used for treating a myelodyspastic syndrome (MDS) and/or an acute myeloid leukemia (AML) in an individual in need thereof.